Original article
NT157 exhibits antineoplastic effects by targeting IRS and STAT3/5 signaling in multiple myeloma
Gustavo Nery de Queiroza, Keli Limaa,b, Livia Bassani Lins de Mirandaa, Eduardo Magalhães Regob,c, Fabiola Trainac,d, João Agostinho Machado-Netoa,
Corresponding author
jamachadoneto@usp.br
Corresponding author at: Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, Av. Prof. Lineu Prestes, 1524, CEP 05508-900, São Paulo, SP, Brazil.
Corresponding author at: Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, Av. Prof. Lineu Prestes, 1524, CEP 05508-900, São Paulo, SP, Brazil.
a Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil
b Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil
c Center for Cell Based Therapy, São Paulo Research Foundation, Ribeirão Preto, SP, Brazil
d Department of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil
